Indian generics escalate pressure on Novo Nordisk's weight-loss drug patent
By Freny Patel ( September 3, 2025, 00:20 GMT | Insight) -- Novo Nordisk's patent battle in India has intensified following coordinated legal challenge against the Danish pharmaceutical giant's blockbuster weight-loss drug, semaglutide, sold under the brand names Wegovy and Ozempic. Six new patent-infringement lawsuits were filed by Hyderabad-based Natco Pharma.Indian pharmaceutical companies have intensified their legal challenge against Novo Nordisk, the Danish drugmaker behind the widely popular weight-loss and diabetes drugs Wegovy and Ozempic. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.